The study compared antineoplastic effects of combined methotrexate and 5-fluorouracil therapy on LI210 lymphoid leukemia in mice according to the schedule of treatment. Methotrexate was administered at doses of: LO w . . 0.5 LOw. 5-Fluorouracil was administered at doses of: 0.2 LO IO , 0.1 LOw, 0.02 LO ro . The parameters characterizing the efficacy of the therapy were survival time of mice inoculated with LI2l0 leukemic cells . . as well as 115 1 excretory capacity of mice inoculated with 1251-iododeoxyuridine-Iabelled leukemic cells. It has been observed that the longest survival time of mice with LI210 leukemia is obtained when methotrexate is administered prior to 5-fluorouracil. Reversing the schedule, or simultaneous administration of the drugs results in shorter survival time. despite the administration of 5-fluorouracil at low doses, ineffective on LI210 leukemia in monotherapy. Cytotoxic effects on LI210 leukemic cells labelled with 1151UDR were present only when methotrexate was administered prior to 5-fluorouracil.
Introduction
Methotrexate and 5-fluorouracil are used together in the treatment of some neoplastic diseases (I . 2. 3) . Interaction between these two drugs is being still investigated to develop a more effective therapy. MTX and FU, despite the differences of their essential antineoplastic properties (4) (5) (6) (7) (8) . . have several characteristics of their biochemical activity in common and are competitive in the utilization of some exoand endogenous compounds for their metabolism in vivo . The obtained results of treatment and toxic effects may be dependent on the used doses. as well as o n the schedule of \YT\: and Fl' adm iniqratio n In the 19~O s th e re~u lt 5 of ill 11m, exrerimcnl' u.; in ,:: se\'eral hi sto logically ditTerent ~re~ o f neoplasIT> indicating a stronger c~10to:\ie elTeet of combin:O'J MTX and Fe treatment with ad mini stra ti on of Fl' preceded by MTX were recei\'ed with enthusia~m (9) (10) (11) (12) . It was. however. observed that such modiiication of the treatment schedule may enhance not only antineoplastic activity but also toxic effects. A reversed schedule of administration was proposed: FU prior to MTX. Pretreatment with FU in normal. non-leukemic mice resulted in the survival of animals. despite the administration of MTX at high doses toxic for MTX monotherapy (13) .
The aim of the present study was to compare the relationships between therapeutic effects of combined treatment with MTX and FU, and the schedule of such treatment. The in vivo development of U2l0 Iymphotic leukemia was investigated in mice subjected to combined therapy with MTX administered at submaximal and maximal doses and FU at low therapeutic doses. The schedules of drug administration were different: FU preceding MTX, MTX and FU adminstered simultaneously and MTX preceding FU. The animals were obsetved for sutvival. and those inoculated with Ll210 leukemic cells labelled with '25I-iododeoxyuridine for excretion of 1251.
Materials and Methods

Animals
Animals were obtained from the Institu' te of Immunology and Experimental Therapy. Polish Academy of Sciences (Wroclaw). 222 male mice of BOF strain, weighting 19-23 g (8) (9) (10) weeks old) were held in guarantine for 7 days after arrival. and fed with standard laboratory diet with water ad libitum.
Leukemia
Lymphoid leukemia Ll2IO cells were obtained from the Institute of Immunology and Experimental Therapy, Polish Academy of Sciences (Wroc\aw). and were maintained by serial passage in the ascitic (1uid of OBA/2 mice. Leukemic cells from the (1uid were resuspended in 0.9% sodium chloride solution and injected i.p. into BDF I recipients. used for the experiments.
Therapeutics
Methotrexate (Lederle) and 5-fluorouracil (Fluoroblastin, Farn1italia) were diluted in 0.9% sodium chloride just before the injection. Drugs were premixed at different concentrations so as to obtain for . all the used doses injection volumes of 0.1 ml/lO g b.w. The time interval separating the administrations of drugs (2h) was adopted according to Robbins et al. (13) . Additionally. MTX and FU were administered as monotherapies at the some doses as those used for combined therapy.
Drug efficacy against leukemia was assessed by calculation of MST according to the method of Geran et 01. (15) and ILS%
'25I-iododeo).yuridine
5-[ 125I]
Iodo-2-deoxyuridine, (, 25 I-iododeoxyuridine, 125IUDR). specific activity 5 Ci/ mg was purchased from Amersham International. Buckinghamshire. England.
125I-iododeoxyuridine assay excretion rate was determined in mice which had been inoculated with Ll210 cells labelled according to the method of Hofer et al. (16) , after the administration of MTX or FU alone, and after combined therapy with those cytostatic agents according to various schedules. L 1210 leukemic cells were collected from peritoneal cavities of DBN2 mice and were transferred to BOF1 recipients in the amount of lOb/mouse. MTX (20) FU (20) MTX ( did not receive any drugs. The excretion rates of 1:>51 were assessed on the basis of measurements of 1:>51 activity remaining in the animal organisms (in vivo) performed during 5-day period after the administration of drugs and expressed as percentages of 1:>51 activity in mice before treatment. The measurements of 1:>51 were also simultaneously performed in control groups I a and lb.
Results Table I presents the survival times of mice inoculated with Ll210 leukemia, after the administration of MTX or FU alone as well as after combined therapy with both drugs, administered at various doses and according to various treatment schedules.
In MTX or FU monotherapies ILS% values higher than, or equal to, 25%, were obtained after the administration of MTX at the doses of 40 mgkg (lLS%=56) and 20 mg/kg (lLso' o=25) and after the administration of FU at the doses of 40 mg kg (lLS%= 25). ILS% value after the 20 mg/kg dose of FU was 19%. The drugs administered at the dose of 4 mg/kg did not increase the survival time of mice with Ll210 leukemia.
In the combined MTX and FU therapy the longest survival time of leukemic mice was obtained with the administration of MTX prior to FU. ILS% values were highest after the following combinations of doses: 20 mg/kg MTX and 40 mg/kg FU-ILS%= 169: MTX and FU at the doses of 20 mg/kg each-ILS%= 112.5. With simultaneous administration of identical combinations of doses. or with the administration of FU before MTX the obtained values of mean survival times were significantly lower. Pretreatment with MTX gave a more favourable therapeutic effect than the simultaneous administration of both drugs at the MTX and FU dose level of 40 mg/kg. In other groups the schedule involving pretreatment with MTX did not result in significantly lower mean survival times of L1210 leukemia mice than other applied schedules of treatment.
In none of the investigated groups simultaneous administration of MTX and FU was more efTective than the schedule consisting in pretreatment with MTX; such a schedule. however. was the least favourable in the case of the highest doses used in the experiments. i.e. 40 mg/kg for both MTX and FU.
ILS% values lower than 25% were obtained after the administration of FU-4 mg/kg before MTX-20 mg/kg and FU-20 mg/kg before. or together with MTX-40 mg/kg. Table 2 presents the changes of 115 1 activity in mice inoculated with L1210 leukemic cells labelled with 115[UDR after the administration of MlX FU. and various schedules of combined therapy utilizing both the drugs. The decreases of activity in untreated mice inoculated with "live" control L1210 cells labelled with 115IUDR and with labelled "dead" L1210 control cells.
11sI was excreted from the mice organisms at significantly higher rates after inoculated with dead L 1210 leukemic cells. than after inoculated with live cells.
MTX administered at the dose of 20 mg/kg. significantly increased the excretion rate of 115 1 in mice inoculated with live L1210 leukemic cells in comparison with its excretion in untreated mice. later. FU, a significant decrease of 115 1 achvlty was observed from the first day in comparison with the untreated group inoculated with live L1210 leukemic cells. On the 5th day 125 1 activity did not difTer significantly from that observed in healthy mice. inoculated with dead L1210 cells. The excretion of 115 1 after simultaneous administration of MTX and FU was not statistically different from the excretion in untreated mice. It was. however. significantly less pronounced than that observed after MTX monotherapy. The administration of FU 2 h before MTX significantly reduced the excretion of 115 1 as compared with that observed after the schedule involving prefeatment with MTX. 115 1 activity on the 5th day did not differ statistically from the activity found in the untreated "live" control group.
Discussion
Higher efficacy of combined therapies as compared with monotherapies in the treatment of neoplastic diseases has been sufficiently documented by clinical and experimental studies. Oncological practice also makes advantage of the interaction between MTX and FU (16) (17) (18) (19) (20) (21) (22) . Biochemical studies have demonstrated that these drugs are synergistic if MTX is administered prior to FU. Pretreatment with MTX enhances the availability of 5-phosphoribosyl-l-pyrophosphate for the processes of formation of active FU metabolites. inhibiting the synthesis of RNA. There are attempts to transfer the results of these experimental studies into the clinical practice (23) . It should be remembered however. that antitumor drugs have a low therapeutic index. Enhancement of cytotoxicity of MTX and FU by biochemical modulation resulting from pretreatment with MTX may increase toxic effects and decrease the therapeutic index. Thus, several authors have proposed the administration of FU prior to MTX or stimultaneous administration of both drugs. Robbins et af. pretreated normal mice with low doses of FU before the administration of MTX at a dose which is lethal in monotherapy. That resulted in the survival of the animals, protection against MTX myelotoxicity and negligible histopathologic changes in the alimentary tract (13) . The in vitro experiments, however, indicate that pretreatment with FU may antagonize cytotoxic activity (24, 25) .
The presented study using Ll2lO mice lymphatic leukemia, has compared in vivo the antineoplastic effects of combined treatment with low doses of FU (0.02, 0.1 and 0.2 LD IO ) and high doses of MTX: 1.0 LOw and 0.5 LDII) administered in various sequences, as well as simultaneously.
From the experiments it follows that the survival time of mice with Ll210 leukemia is longest if MTX is administered prior FU. A reversed schedule or simultaneous administration of both drugs result in shorter survival times in most of the investigated groups, despite the administration of FU at low doses, ineffective against Ll210 leukemia in monotherapy.
Hofer et al. proposed the use of 1251UDR for the assessment of mechanism of antineoplastic drug activity. Radioactive iodine with deoxyuridine hound in the Ll210 cells, is released after the death or the cells. Determination of the rate of 125 1 excretion from the organisms of mice inoculated with labelled L 1210 leukemic cells after the administration of the investigated antineoplastic agent allows assessment of its cytocidal (cytotoxic) activity. Using this method. Hofer et al. observed that MTX causes the death of Ll210 leukemic cells (16) .
From our own studies if follows that the cytotoxic effects occurs only if MTX is administered before FU. Administration prior or together with MTX does not result in a cytocidal effect on Ll2l0 leukemic cells labelled with 125IUDR.
